產(chǎn)品名稱：Ridaforolimus 產(chǎn)品貨號(hào)：LC R-7040 產(chǎn)品規(guī)格：100 MG Ridaforolimus (the name has been changed from "deforolimus") is an immunosuppressant and a novel small-molecule inhibitor of the protein mammalian target of rapamycin (mTOR). Ridaforolimus inhibits cancer cell growth, cell division, metabolism, and angiogenesis by blocking mTOR. Mahalingam, D., et al. "Targeting the mTOR pathway using deforolimus in cancer therapy." Future Oncol. 5: 291-303 (2009). Ridaforolimus had an antitumor activity in >85% of patients with advanced solid tumors. Rivera, V.M., et al. "Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor." J. Clin. Oncol. 23: 3033 (2005). Ridaforolimus has low toxicity profiles and promising clinical efficacy in patients with advanced sarcomas. Chawla, S.P., et al. "Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas." J. Clin. Oncol. 24: 9505 (2006). The level of phosphorylated S6 ribosomal protein expression was a marker of early tumor response to ridaforolimus. Iwenofu, O.H., et al. "Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy." Mod. Pathol. 21: 231-237 (2008). MEK inhibitors in combination with the mTOR inhibitor, rapamycin or its analogue ridaforolimus, exhibited synergism in human lung cancer cell lines by inhibiting proliferation rather than promoting cell death. Legrier, M.E., et al. "Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression." Cancer Res. 67: 11300-11308 (2007). Another CAS number previously assigned to ridaforolimus, 697252-87-2, has been deleted by CAS and is no longer in use. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A
滬公網(wǎng)安備 31011002002623號(hào)
